Clinical Outcomes of Antrectomy for Patients With Multiple Type I Gastric Neuroendocrine Tumors: A Case Series
DEN Open · 2027-04 · 7 (1)
DOI: 10.1002/deo2.70363 ↗Kurz gefasst
Fachartikel in der Zeitschrift DEN Open, online erschienen am 15.06.2026. Verfasst von Yuki Morita und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Type I gastric neuroendocrine tumors (T1‐GNETs) are frequently associated with autoimmune gastritis and typically present as multiple lesions. The treatment options for T1‐GNETs include endoscopic resection (ER), surgical resection, and pharmaceutical therapies. Antrectomy is reportedly an effective treatment for multiple T1‐GNETs; however, its efficacy and indication remain unclear. In this study, we aimed to assess the efficacy of antrectomy in patients with multiple T1‐GNETs.
Methods
We retrospectively evaluated the clinical outcomes of eight patients with persistent multiple T1‐GNETs in the gastric remnant following antrectomy from 2005 to 2023.
Results
All eight patients (median age: 60 years, male‐to‐female ratio 1:3) had body‐dominant atrophic gastritis. Median preoperative serum gastrin levels were 4800 (range, 2400–11,000) pg/mL. Preoperative endoscopy revealed 20 in five patients. Antrectomy was performed as a primary surgery in three patients, as a completion surgery following non‐curative ER in two patients, and a combination therapy with pre‐antrectomy ER in three patients. Median serum gastrin levels decreased to 68 (range, 25–120) pg/mL during the median followup of 56 (range, 14–72 months). Tumor regression was observed in two patients and disappearance in six, with no recurrence or deaths.
Conclusion
We assessed the residual T1‑GNETs post‐antrectomy and discovered either regression or disappearance in all cases. Normalized serum gastrin levels following antrectomy may have contributed to this outcome. On the basis of our findings, the combination of antrectomy and ER resulted in tumor regression that may represent a potential organ‐preserving approach for patients with multiple T1‐GNETs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.
- Department of Gastroenterology Tonan Hospital Sapporo Hokkaido Japan.
- Department of Internal Medicine Division of Gastroenterology Landspítali University Hospital Reykjavík Iceland.
- Department of Pathology Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.
- Division of Pathology Cancer Institute, Japanese Foundation for Cancer Research Tokyo Japan.
- Department of Gastric Surgery Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.
ORCID-Profile: Yuki Morita, Toshiaki Hirasawa
Zitieren
APA
Morita, Y., Namikawa, K., Nakano, K., Kurihara, W., Yamamoto, H., Horiuchi, Y., Ishiyama, A., Yoshio, T., Nunobe, S., & Hirasawa, T. (2027). Clinical Outcomes of Antrectomy for Patients With Multiple Type I Gastric Neuroendocrine Tumors: A Case Series. DEN Open, 7(1). https://doi.org/10.1002/deo2.70363
Vancouver
Morita Y, Namikawa K, Nakano K, Kurihara W, Yamamoto H, Horiuchi Y, et al. Clinical Outcomes of Antrectomy for Patients With Multiple Type I Gastric Neuroendocrine Tumors: A Case Series. DEN Open. 2027;7(1). doi:10.1002/deo2.70363
BibTeX
@article{Morita2027,
author = {Morita, Yuki and Namikawa, Ken and Nakano, Kaoru and Kurihara, Wataru and Yamamoto, Hiroyuki and Horiuchi, Yusuke and Ishiyama, Akiyoshi and Yoshio, Toshiyuki and Nunobe, Souya and Hirasawa, Toshiaki},
title = {Clinical Outcomes of Antrectomy for Patients With Multiple Type I Gastric Neuroendocrine Tumors: A Case Series},
journal = {DEN Open},
year = {2027},
volume = {7},
number = {1},
doi = {10.1002/deo2.70363}
}
EUVIMED